Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide in Alzheimer's Disease
NCT05891496Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2023
- Primary completion
- Aug 2024
- Countries
- 6
01
Overview
A Phase 3 trial of semaglutide in Alzheimer's disease (AD), sponsored by Novo Nordisk. Started Jun 2023; status: completed.
02
Drugs
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05891496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05891496.